openPR Logo
Press release

Brain Metastases Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

05-14-2024 09:30 PM CET | Health & Medicine

Press release from: ABNewswire

Brain Metastases Pipeline, FDA Approvals, Unmet Needs,

DelveInsight's, "Brain Metastases Pipeline Insight 2024" report provides comprehensive insights about 40+ Brain Metastases companies and 45+ pipeline drugs in Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including clinical and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Brain Metastases Pipeline Report

* DelveInsight's Brain Metastases pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Brain Metastases treatment.
* The leading companies working in the Brain Metastases Market include HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera , and others.
* Promising Brain Metastases Pipeline Therapies in the various stages of development include 8F fluciclovine, BT-M01, RRx-001 + WBRT, BMX-001, Veliparib, ANG1005, Keynatinib, and others.
* May 2024:- Emroy University- Pilot Study of Pembrolizumab and Stereotactic Radio-Surgery (SRS) for Patients With Melanoma or Non-Small Cell Lung Cancer (NSCLC) Brain Metastases (BM). This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

Request a sample and discover the recent advances in Brain Metastases Treatment Drugs @ Brain Metastases Pipeline Outlook Report [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

In the Brain Metastases pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Brain Metastases Overview

Brain metastases are a common complication of cancer and the most common type of brain tumor. Anywhere from 10% to 26% of patients who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured using conventional therapies, long-term survival and palliation are possible with minimal adverse effects to patients. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for patients as survival continues to increase.

Find out more about Brain Metastases Therapeutics Assessment @ Brain Metastases Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Brain Metastases Emerging Drugs Profile

* ANG1005: Angiochem
* Azeliragon: Cantex Pharmaceuticals, Inc.
* AZD3759: Alpha Biopharma Ltd.

Brain Metastases Pipeline Therapeutics Assessment

There are approx. 45+ key companies which are developing the therapies for Brain metastases. The Brain Metastases companies which have their Brain metastases drug candidates in the most advanced stage, i.e. phase III.

DelveInsight's Brain Metastases Pipeline Report covers around 45+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Brain Metastases Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Learn more about the emerging Brain Metastases Pipeline Therapies @ Brain Metastases Clinical Trials Assessment [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Brain Metastases Pipeline Report

* Coverage- Global
* Brain Metastases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Brain Metastases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Brain Metastases Companies- HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera , and others.
* Brain Metastases Pipeline Therapies- 8F fluciclovine, BT-M01, RRx-001 + WBRT, BMX-001, Veliparib, ANG1005, Keynatinib , and others.

Dive deep into rich insights for new drugs for Brain Metastases Treatment, Visit @ Brain Metastases Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Brain metastases: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Brain metastases- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* ANG1005: Angiochem
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Paxalisib: Kazia Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MW151: ImmunoChem Therapeutics, LLC
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* JBI-2174: Jubilant Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Brain metastases Key Companies
* Brain metastases Key Products
* Brain metastases- Unmet Needs
* Brain metastases- Market Drivers and Barriers
* Brain metastases- Future Perspectives and Conclusion
* Brain metastases Analyst Views
* Brain metastases Key Companies
* Appendix

For further information on the Brain Metastases Pipeline therapeutics, reach out to Brain Metastases Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=brain-metastases-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Brain Metastases Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) here

News-ID: 3496492 • Views:

More Releases from ABNewswire

Alset Capital Strengthens AI Asset Base After Taking A 49% Stake In Two Innovative Sector Companies ($ALSCF)
Alset Capital Strengthens AI Asset Base After Taking A 49% Stake In Two Innovati …
Alset Capital Inc.'s (TSXV: KSUM) (OTC: ALSCF) (FSE:1R60, WKN: A3ESVQ) mission is to drive significant shareholder value through the acquisition and development of AI assets. Alset aims to position its investment portfolio to become the leading publicly listed pure-play AI computing provider. Accelerating that mission, Alset announced its successful listing on the Frankfurt Stock Exchange (the "FSE") under the trading symbol "1R60", WKN: A3ESVQ, ISIN: CA02115L2003, and to the OTC
Treatment.com AI Inc. (TRUE.CN) Advances AI in Healthcare with Strategic Moves
Treatment.com AI Inc. (TRUE.CN) Advances AI in Healthcare with Strategic Moves
The debate on whether the AI sector is in a bubble is understandable given the rapid rise and immense market value of AI-driven companies, but recent developments and substantial investments suggest otherwise. Nvidia has become a $2 trillion company, Reddit highlighted AI in its IPO, Amazon invested $4 billion in AI through Anthropic, and Apple increased R&D spending for AI, even discussing potential partnerships with Google's Gemini AI platform. These
How to Prepare Children for the First Dental Visit, Explained by Dr. Sandra Thompson
How to Prepare Children for the First Dental Visit, Explained by Dr. Sandra Thom …
Learn expert tips from Dr. Sandra Thompson on how to prepare your children for their first dental visit. Discover strategies to ensure a positive experience and promote lifelong oral health. Desert Kids Dental, located at 9859 W Deer Springs Way STE 110 in Las Vegas, is revolutionizing the pediatric dentistry experience with their comprehensive, child-friendly approach. Under the expert guidance of Dr. Sandra Thompson, this clinic promises not only top-tier dental
GROOMIT Welcomes Dhruv Piplani as Financial Advisor to the Board of Advisors
GROOMIT Welcomes Dhruv Piplani as Financial Advisor to the Board of Advisors
GROOMIT, a New York-based company famous for its mobile pet grooming services, is proud to announce [https://www.linkedin.com/pulse/dhruv-piplani-from-wall-street-pet-grooming-industry-new-pt3wf/] the addition of Dhruv Piplani to its Board of Advisors. Piplani has global expertise and extensive experience working at investment banks. He will also assume an active role as Financial Advisor to the CEO, having served as an investor in GROOMIT for over three years. "We are thrilled to welcome Dhruv Piplani to our

All 5 Releases


More Releases for Brain

Retro X Focus Nootropic Brain Booster - SUPERCHARGED BRAIN PERFORMANCE!
Retro X Focus Nootropic Brain Booster is a state-of-the-art nootropic that employs vitamins, vital nutrients, plus amino acids to assist you to think quicker, cleverer, smarten your memory, and improve attention and leave you feeling invigorated. The water-soluble extracts, which are useful in product additives, function to rejuvenate studying approaches and thinking. Official Online Store - https://www.allnutritionhub.com/get-retro-x-focus-nootropic How does the Retro X Focus Function? It is common knowledge that we must work out
Cogni Brain 360 - Does It Really Work For Brain Health!
Cogni Brain 360 Some signs of cerebrum depression include mental and emotional upheavals and feelings that are not predictable. Many of these symptoms occur when your brain isn't in a stable state or not receiving the necessary supplements. Official Website: CLICK HERE=> https://dmocoz.com/order-cognibrain360 Cogni Brain 360 - What is it? Cogni Brain 360This causes mental decrease in a normal setting and accelerates psychological rot. It can also cause severe and long-lasting mental damage
Brain Cancer Diagnostics Market: Increase in Prevalence of Brain Cancer Worldwid …
The scope of the brain cancer diagnostics market includes diagnostic type, cancer type, end user, and region. The brain cancer diagnostics market is analyzed based on regions such as North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the brain cancer diagnostics market, emphasizing various parameters such as market trends, technological advancements, market dynamics, and competitive
Geehii Brain Pills Review-Does Geehii Brain Work-Complete Info
Your thoughts is what makes you who you're. It consists of your recollections, personality, and selection-making strategies. We need to inform you about a supplement known as Geehii Brain Pills. This is a method that aid mind fitness and help you reap your complete capacity. After all, you consume proper and workout to maintain your body wholesome, why wouldn’t you do something to make certain you mind remains as wholesome
Wireless Brain Sensors Market 2017- EMOTIV, Advanced Brain Monitoring, Muse, Neu …
Apex Market Reports, recently published a detailed market research study focused on the "Wireless Brain Sensors Market" across the global, regional and country level. The report provides 360° analysis of "Wireless Brain Sensors Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Wireless Brain Sensors industry, and estimates the future trend of
4th International conference on Brain Disorders and Brain Injury
Dear Members, I hope you are doing well This is Karlin Zoe; we would like to invite at our upcoming 4th International Conference on Brain Disorder and Brain Injury on August 14-16, 2017 at Toronto, Canada Participate at this conference and earn up to 20 AMA PRA Category 1 Credits TM Mark your calendar as busy on August 14-16, 2017; they are the official dates for the Brain Injury 2017. Participation benefits: Claim CME